ArticleBMJ open2026

CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial.

Ruihong Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.